STOCK TITAN

Blueprint Medicines Corp - BPMC STOCK NEWS

Welcome to our dedicated page for Blueprint Medicines news (Ticker: BPMC), a resource for investors and traders seeking the latest updates and insights on Blueprint Medicines stock.

Blueprint Medicines Corporation (Nasdaq: BPMC) is a leading biopharmaceutical company focused on developing highly selective and potent kinase therapies to treat genomically defined diseases. With a deep understanding of the genetic blueprint of cancer and other kinase-driven diseases, Blueprint Medicines leverages its proprietary chemical compounds to craft therapies for new and challenging targets.

Blueprint Medicines boasts a robust pipeline, spearheaded by AYVAKIT (avapritinib), a drug designed for the treatment of systemic mastocytosis (SM) and other related disorders. AYVAKIT has secured approvals in the U.S. and Europe, marking significant strides in offering therapeutic solutions for patients with advanced SM, indolent systemic mastocytosis (ISM), and highly specific mutations in gastrointestinal stromal tumors.

Among its promising pipeline, Blueprint Medicines is developing several innovative candidates, including BLU-808, aimed at treating mast cell disorders like chronic urticaria and sleep disruptions, and BLU-222, focusing on breast cancer treatment. The company consistently demonstrates its commitment to transforming patient care through groundbreaking research and development.

Recent achievements highlight the company's growth trajectory. In Q3 2023, Blueprint reported strong revenue growth following AYVAKIT's successful launch for ISM, supported by its favorable clinical profile. The European Medicines Agency has recently given a positive opinion for AYVAKYT, extending its indication to ISM patients, reflecting the company's continued expansion in global markets.

Blueprint Medicines remains dedicated to advancing its clinical pipeline, optimizing operational efficiency, and securing strategic partnerships to harness market potential. The company is committed to delivering innovative therapies, offering hope and improved outcomes for patients worldwide.

  • Core Business: Development of selective kinase therapies for genomically defined diseases.
  • Key Products: AYVAKIT/AYVAKYT for systemic mastocytosis and gastrointestinal stromal tumors.
  • Current Projects: Development of BLU-808, BLU-222, and other therapies targeting mast cell disorders and various cancers.
  • Recent Achievements: Strong revenue growth, positive EMA opinion, expansion in Europe.
  • Partnerships: Collaborations with global healthcare agencies and ongoing clinical trials.
Rhea-AI Summary
Blueprint Medicines Corporation (Nasdaq: BPMC) announces positive PIONEER trial results for AYVAKIT in patients with indolent systemic mastocytosis and preclinical data for BLU-808, showcasing long-term efficacy, safety, and best-in-class potential. The company is transforming care for mast cell disorders with a focus on patient outcomes and expanding treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
none
-
Rhea-AI Summary
Blueprint Medicines Corporation (BPMC) achieved $204.2 million in AYVAKIT net product revenues in 2023, with $71.0 million in Q4. They anticipate global AYVAKIT net product revenue of $360-390 million in 2024, showing over 80% year-over-year growth. Nine presentations highlighting AYVAKIT's safety and efficacy were accepted for the 2024 AAAAI Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.02%
Tags
-
Rhea-AI Summary
Blueprint Medicines Corporation (BPMC) granted non-qualified stock options and restricted stock units (RSUs) to three new employees under its 2020 Inducement Plan. The options have an exercise price of $79.88 per share and will vest over time, subject to the employees' continued employment. The RSUs will also vest over time, subject to the same conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
Rhea-AI Summary
Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call and webcast on February 15, 2024, to report its fourth quarter and full year 2023 financial results and provide a corporate update. The call will be accessible via phone or webcast, with the archived webcast available for 30 days after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
conferences earnings
-
Rhea-AI Summary
Blueprint Medicines Corporation (BPMC) outlines 2024 strategy for AYVAKIT® launch in indolent systemic mastocytosis, advancing BLU-808 into clinical development, and maintaining durable cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
-
Rhea-AI Summary
Blueprint Medicines Corporation (BPMC) Grants Stock Options and RSUs to New Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
Rhea-AI Summary
Blueprint Medicines Corporation (Nasdaq: BPMC) announced that CEO Kate Haviland will present a corporate overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. A live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
conferences
-
Rhea-AI Summary
Blueprint Medicines Corporation (Nasdaq: BPMC) announced that the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe, designed to potently and selectively target KIT D816V, the primary underlying driver of the disease. The approval is based on data from the PIONEER trial, where AYVAKYT achieved significant improvements across a broad range of symptoms with a safety profile comparable to placebo. The majority of patients living with SM have ISM, and there are approximately 40,000 people living with ISM in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
none
-
Rhea-AI Summary
Blueprint Medicines Corporation (Nasdaq: BPMC) announced data from the HARBOR Part 1 trial of elenestinib in indolent systemic mastocytosis at the 65th American Society of Hematology Annual Meeting. Elenestinib demonstrated being well-tolerated, clinically active, and showed broad symptom improvement. The company continues to advance its scientific understanding and treatment of systemic mastocytosis to expand and extend its SM franchise leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Blueprint Medicines Corporation (BPMC) granted non-qualified stock options and restricted stock units (RSUs) to two new employees under its 2020 Inducement Plan. The options have an exercise price of $72.05 per share and will vest over time, subject to continued employment. The RSUs will also vest over time, subject to the same condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none

FAQ

What is the current stock price of Blueprint Medicines (BPMC)?

The current stock price of Blueprint Medicines (BPMC) is $96.57 as of February 28, 2025.

What is the market cap of Blueprint Medicines (BPMC)?

The market cap of Blueprint Medicines (BPMC) is approximately 5.7B.

What is Blueprint Medicines Corporation's primary focus?

Blueprint Medicines Corporation focuses on developing highly selective and potent kinase therapies for the treatment of genomically defined diseases.

What is AYVAKIT?

AYVAKIT (avapritinib) is a kinase inhibitor approved for the treatment of various forms of systemic mastocytosis (SM) and specific mutations in gastrointestinal stromal tumors.

What recent achievements has Blueprint Medicines made?

Recent achievements include strong revenue growth following AYVAKIT’s launch for indolent systemic mastocytosis (ISM) and a positive opinion from the European Medicines Agency for expanding AYVAKYT’s indications.

What are some key products in Blueprint Medicines' pipeline?

Key products in the pipeline include BLU-808 for mast cell disorders and BLU-222 for breast cancer treatment.

What sets Blueprint Medicines apart in drug development?

Blueprint Medicines stands out for its deep understanding of genetic drivers of disease and its proprietary library of novel chemical compounds, enabling the creation of kinase therapies targeting difficult-to-drug genomic subsets.

How does Blueprint Medicines contribute to patient care?

By focusing on genomically defined subsets of patients, Blueprint Medicines aims to create more efficient clinical development paths, improving the likelihood of successful outcomes and better patient care.

Where can I learn more about Blueprint Medicines’ clinical trials?

Information about ongoing or planned clinical trials can be found at blueprintclinicaltrials.com or clinicaltrials.gov.

How can I contact Blueprint Medicines for more information?

For more information, visit their website at www.BlueprintMedicines.com, or follow them on Twitter (@BlueprintMeds) and LinkedIn.

What are the company’s future plans for AYVAKIT?

Blueprint Medicines plans to continue expanding AYVAKIT's indications and market reach, particularly in Europe and the U.S., driven by its strong clinical profile and patient demand.

What are the primary therapeutic areas Blueprint Medicines is focusing on?

Blueprint Medicines is focusing on allergy/inflammation and oncology/hematology, with a strategic investment in therapeutic areas leveraging their core expertise and business infrastructure.
Blueprint Medicines Corp

Nasdaq:BPMC

BPMC Rankings

BPMC Stock Data

5.66B
63.00M
1.27%
104.9%
8.09%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE